MCE products for research use only. We do not sell to patients.

Fucoxanthin

MCE China：Fucoxanthin

Brand：MedChemExpress (MCE)

Cat. No.HY-N2302

CAS：3351-86-8

Synonyms：all-trans-Fucoxanthin

Purity：98.99%

Storage：Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month

Shipping：Room temperature in continental US; may vary elsewhere.

Description：Fucoxanthin (all-trans-Fucoxanthin) is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities.

In Vitro：Fucoxanthin (2.8-6.2 µM, 24 h) shows obvious bacteriostatic effect on all tested Mtb strains, with MIC values of 2.8-4.1 µM[4]. Fucoxanthin (0-25 µM, 24 h) inhibits the proliferation of HeLa and SiHa cervical cancer cell lines and promotes cell stasis in the G0/G1 cell cycle phase[5]. Fucoxanthin (10 µM, 12 h) inhibits the cell viability of HTLV-1-infected T cell lines by inducing G1 cell cycle arrest and apoptosis, thereby exhibiting anticancer activity[7]. Fucoxanthin (0-100 µg/mL, 24 h) dose-dependent inhibits the expression of TNF-α, PGE2, iNOS and COX-2 proteins in RAW 264.7 cells[8].

In Vivo：Fucoxanthin (10-2000 mg/kg, p.o.) does not cause death or abnormal appearance in ICR mice and rats[3]. Fucoxanthin (10-50 mg/kg/day, p.o.) can protect the cadmium-induced renal injury mouse model by improving the antioxidant capacity of mice[9]. Fucoxanthin (0.1-10 mg/kg, i.v.) shows a dose-dependent anti-ocular inflammatory effect on EIU (endotoxin-induced uveitis) [8].

IC50 & Target：PPARγ UCP1 PPARα iNOS Caspase 3 Caspase-8 Caspase 9 SOD ERK2

Hot selling product：Girentuximab  | Pyrvinium pamoate  | AN-12-H5 intermediate-1  | BAY 2666605  | Thymalfasin  | Dehydrotumulosic acid  | Nemolizumab  | Sodium 2-mercaptoethanesulfonate  | Mirin  | Tetrahydropalmatine

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Gammone MA, et al. Anti-obesity activity of the marine carotenoid fucoxanthin. Mar Drugs. 2015 Apr 13;13(4):2196-214.  [Content Brief]

[2]. Méresse S, Fodil M, Fleury F, Chénais B. Fucoxanthin, a Marine-Derived Carotenoid from Brown Seaweeds and Microalgae: A Promising Bioactive Compound for Cancer Therapy. Int J Mol Sci. 2020;21(23):9273.  [Content Brief]

[3]. Yoshimi Niwano, et al. In Vivo and in Vitro Toxicity Studies of Fucoxanthin, a Marine Carotenoid. null. 2011;0 (0):319-328.

[4]. Šudomová M, et al. A Microbiological, Toxicological, and Biochemical Study of the Effects of Fucoxanthin, a Marine Carotenoid, on Mycobacterium tuberculosis and the Enzymes Implicated in Its Cell Wall: A Link Between Mycobacterial Infection and Autoimmune Diseases. Mar Drugs. 2019 Nov 14;17(11):641.  [Content Brief]

[5]. Ye G, et al. Fucoxanthin may inhibit cervical cancer cell proliferation via downregulation of HIST1H3D. J Int Med Res. 2020 Oct;48(10):300060520964011.  [Content Brief]

[6]. Okuzumi J, et al. Inhibitory effects of fucoxanthin, a natural carotenoid, on N-myc expression and cell cycle progression in human malignant tumor cells. Cancer Lett. 1990 Nov 19;55(1):75-81.  [Content Brief]

[7]. Ishikawa C, et al. Anti-adult T-cell leukemia effects of brown algae fucoxanthin and its deacetylated product, fucoxanthinol. Int J Cancer. 2008 Dec 1;123(11):2702-12.  [Content Brief]

[8]. Shiratori K, et al. Effects of fucoxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Exp Eye Res. 2005 Oct;81(4):422-8.  [Content Brief]

[9]. Yang H, et al. Role of Fucoxanthin towards Cadmium-induced renal impairment with the antioxidant and anti-lipid peroxide activities. Bioengineered. 2021 Dec;12(1):7235-7247.  [Content Brief]